Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy.
Boileau C, Deforges S, Peret A, Scavarda D, Bartolomei F, Giles A, Partouche N, Gautron J, Viotti J, Janowitz H, Penchet G, Marchal C, Lagarde S, Trebuchon A, Villeneuve N, Rumi J, Marissal T, Khazipov R, Khalilov I, Martineau F, Maréchal M, Lepine A, Milh M, Figarella-Branger D, Dougy E, Tong S, Appay R, Baudouin S, Mercer A, Smith JB, Danos O, Porter R, Mulle C, Crépel V. Boileau C, et al. Among authors: figarella branger d. Ann Neurol. 2023 Oct;94(4):745-761. doi: 10.1002/ana.26723. Epub 2023 Jul 6. Ann Neurol. 2023. PMID: 37341588
A potential diagnostic pitfall: Primary synovial sarcoma of the central nervous system.
Tauziede-Espariat A, Macagno N, Pissaloux D, Figarella-Branger D, Appay R, Bochaton D, Tazi S, Kauv P, Hasty L, Métais A, Chrétien F, Varlet P. Tauziede-Espariat A, et al. Free Neuropathol. 2022 Apr 26;3:3-11. doi: 10.17879/freeneuropathology-2022-3811. eCollection 2022 Jan. Free Neuropathol. 2022. PMID: 37284151 Free PMC article.
A cohort study of CNS tumors in Multiple Endocrine Neoplasia Type 1.
Graillon T, Romanet P, Camilla C, Gelin C, Appay R, Roche C, Lagarde A, Mougel G, Farah K, Le Bras M, Engelhardt J, Kalamarides M, Peyre M, Amelot A, Emery E, Magro E, Cebula H, Aboukais R, Bauters C, Jouanneau E, Berhouma M, Cuny T, Dufour H, Loiseau H, Figarella-Branger D, Bauchet L, Binquet C, Barlier A, Goudet P. Graillon T, et al. Among authors: figarella branger d. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-3308. Online ahead of print. Clin Cancer Res. 2024. PMID: 38630553
GD3 ganglioside is a promising therapeutic target for glioma patients.
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. Hein V, et al. Among authors: figarella branger d. Neurooncol Adv. 2024 Mar 19;6(1):vdae038. doi: 10.1093/noajnl/vdae038. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38590763 Free PMC article. Review.
Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GBM).
Harlay V, Appay R, Bequet C, Petrirena G, Campello C, Barrié M, Autran D, Graillon T, Boissonneau S, Dufour H, Figarella-Branger D, Padovani L, Barlier A, Nanni I, Tabouret E, Chinot O. Harlay V, et al. Among authors: figarella branger d. Neurooncol Pract. 2023 May 30;10(6):536-543. doi: 10.1093/nop/npad028. eCollection 2023 Dec. Neurooncol Pract. 2023. PMID: 38009116 Free article.
Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms.
Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, Pinna G, Failes TW, Arndt GM, Morando P, Baeza-Kallee N, Colin C, Chinot O, Braguer D, Morelli X, André N, Carré M, Tabouret E, Figarella-Branger D, Le Grand M, Pasquier E. Ariey-Bonnet J, et al. Among authors: figarella branger d. EBioMedicine. 2023 Sep;95:104752. doi: 10.1016/j.ebiom.2023.104752. Epub 2023 Aug 10. EBioMedicine. 2023. PMID: 37572644 Free PMC article.
Deciphering the Action of Neuraminidase in Glioblastoma Models.
Baeza-Kallee N, Bergès R, Hein V, Cabaret S, Garcia J, Gros A, Tabouret E, Tchoghandjian A, Colin C, Figarella-Branger D. Baeza-Kallee N, et al. Among authors: figarella branger d. Int J Mol Sci. 2023 Jul 19;24(14):11645. doi: 10.3390/ijms241411645. Int J Mol Sci. 2023. PMID: 37511403 Free PMC article.
A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p/19q Codeleted Oligodendrogliomas.
Gilhodes J, Meola A, Cabarrou B, Peyraga G, Dehais C, Figarella-Branger D, Ducray F, Maurage CA, Loussouarn D, Uro-Coste E, Cohen-Jonathan Moyal E, Pola Network. Gilhodes J, et al. Among authors: figarella branger d. Cancers (Basel). 2023 Jun 6;15(12):3067. doi: 10.3390/cancers15123067. Cancers (Basel). 2023. PMID: 37370678 Free PMC article.
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
Sahm F, Brandner S, Bertero L, Capper D, French PJ, Figarella-Branger D, Giangaspero F, Haberler C, Hegi ME, Kristensen BW, Kurian KM, Preusser M, Tops BBJ, van den Bent M, Wick W, Reifenberger G, Wesseling P. Sahm F, et al. Among authors: figarella branger d. Neuro Oncol. 2023 Oct 3;25(10):1731-1749. doi: 10.1093/neuonc/noad100. Neuro Oncol. 2023. PMID: 37279174 Free PMC article.
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network. Esparragosa Vazquez I, et al. Among authors: figarella branger d. Eur J Neurol. 2023 Sep;30(9):2879-2883. doi: 10.1111/ene.15873. Epub 2023 May 31. Eur J Neurol. 2023. PMID: 37204066
576 results